Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 9	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 14	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 15	DEC 18	CA/CAplus patent kind codes updated
NEWS 16	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 18	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 20	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:23:33 ON 19 JAN 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:23:43 ON 19 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2
DICTIONARY FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525566.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:24:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          331 TO     1029
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 12:24:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      654 TO ITERATE

100.0% PROCESSED      654 ITERATIONS                               52 ANSWERS
SEARCH TIME: 00.00.01

L3            52 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 12:24:08 ON 19 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Jan 2007 VOL 146 ISS 5
FILE LAST UPDATED: 18 Jan 2007 (20070118/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d abs bib hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkyl; R2 and R3 independently = OH, alkoxy, cycloalkoxy, etc. or R2 and R3 together are alkylenedioxy group; R4 = H, halo, NO2, etc.; R5 = H, alkyl, phenylalkyl, etc.; R6 = alkyl, phenylalkyl or (un)substituted arylalkyl; R7 = alkyl and n = 1-2 or R7 = H and n = 1-3] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of PDE3/4. Thus, e.g., II was prepared by amidation of 4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl)benzoic acid (preparation given) with 3-isopropoxypropyl-amine. The inhibitory activity of I towards PDE3 and PDE4 was evaluated using radioactive enzyme assays and it was revealed that compds. of the invention possessed -log IC50 values in the range of 7.8 up to 9.9 mol/L for PDE4 and in the range of 5.8 up to 7.8 mol/L for PDE3. I as inhibitor of PDE3/4 should prove useful in the treatment of respiratory disorders and dermatoses. Pharmaceutical compns. comprising I are disclosed.
AN 2005:1049863 CAPLUS
DN 143:347067
TI Preparation of phenyl benzonaphthyridine derivatives as PDE3/4 inhibitors
IN Kautz, Ulrich; Hatzelmann, Armin; Barsig, Johannes; Marx, Degenhard; Kley,

Hans-Peter; Flockerzi, Dieter
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090345	A1	20050929	WO 2005-EP51204	20050316
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005223386	A1	20050929	AU 2005-223386	20050316
	CA 2559200	A1	20050929	CA 2005-2559200	20050316
	EP 1732925	A1	20061220	EP 2005-717070	20050316
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRAI	EP 2004-101101	A	20040317		
	EP 2004-101111	A	20040318		
	WO 2005-EP51204	W	20050316		

OS MARPAT 143:347067
IT 865355-32-4P 865355-33-5P 865355-34-6P
865355-35-7P 865355-37-9P 865355-38-0P
865355-39-1P 865355-40-4P 865355-41-5P
865355-42-6P 865355-43-7P 865355-44-8P
865355-45-9P 865355-46-0P 865355-47-1P
865355-48-2P 865355-49-3P 865355-50-6P
865355-51-7P 865355-52-8P 865355-53-9P
865355-54-0P 865355-55-1P 865355-56-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph benzonaphthyridine derivs. as PDE3/4 inhibitors)
RN 865355-32-4 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[3-(1-methylethoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-33-5 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-methoxy-1-methylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-34-6 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[1-(methoxymethyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-35-7 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(3-ethoxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-37-9 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-ethyl-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-38-0 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(2-methoxyethyl)-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-39-1 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(2-methoxyethyl)-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-40-4 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1R)-1-methyl-2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-41-5 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1S)-1-methyl-2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-42-6 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[1-methyl-3-(phenylmethoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-43-7 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-methoxy-1-methylethyl]-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-44-8 CAPLUS
CN Benzamide, N-cyclohexyl-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-45-9 CAPLUS
CN Benzamide, N-cyclohexyl-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(3-methoxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-46-0 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-47-1 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(2-methoxyethyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-48-2 CAPLUS
CN Benzamide, N-(3-butoxypropyl)-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 865355-49-3 CAPLUS
CN Benzamide, N-[(1S)-2-[(3,5-dimethoxyphenyl)methoxy]-1-methylethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-50-6 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1S)-1-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-51-7 CAPLUS
CN Benzamide, N-[(1S)-2-[(4-cyanophenyl)methoxy]-1-methylethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-52-8 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-[(4-methoxyphenyl)methoxy]-1-methylethyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-53-9 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1S)-1-methyl-2-(3-phenylpropoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-54-0 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-methyl-N-[(1S)-3-methyl-1-[(phenylmethoxy)methyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-55-1 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-1-methyl-2-(phenylmethoxy)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865355-56-2 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-1-methyl-2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d abs bib hitstr 2

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB The title compds. I [R1 = C1-C4 alkyl; R2, R3 = OH, C1-C4 alkoxy, C3-C7 cycloalkoxy, C3-C7 cycloalkylmethoxy, fluorinated C1-C4 alkoxy; or R2/R3 = C1-C2 alkylenedioxy group; R4 = H, halo, NO2, C1-C4 alkyl, CF3, C1-C4 alkoxy; R5 = H or C1-C8 alkyl; R6 = H, C1-C8 alkylcarbonyl, C3-C7 cycloalkylcarbonyl, C3-C7 cycloalkylmethylcarbonyl, C1-C4 arylcarbonyl, arylalkylcarbonyl; n = 1-2] were prepared as PDE3/4 inhibitors for the treatment of respiratory disorders and/or dermatoses. Thus, reaction of 4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl)benzoic acid with phenyl-acetic acid (S)-2-isopropylamino-Pr ester hydrochloride yielded compound II. The latter inhibits PDE4 and PDE3 with -log IC50 = 9.8, 7.3 mol/L, resp.

AN 2004:220332 CAPLUS

DN 140:270839

TI Preparation of phenylbenzonaphthyridine derivatives as PDE3/4 inhibitors

IN Flockerzi, Dieter; Hummel, Rolf-peter; Reutter, Felix; Flockerzi, Dieter; Hummel, Rolf-peter; Reutter, Felix

PA Altana Pharma Ag, Germany

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022557	A1	20040318	WO 2003-EP9617	20030829
	W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2496731	A1	20040318	CA 2003-2496731	20030829

	AU 2003264132	A1	20040329	AU 2003-264132	20030829
	EP 1537109	A1	20050608	EP 2003-793772	20030829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005539055	T	20051222	JP 2004-533426	20030829
	US 2006167034	A1	20060727	US 2005-525566	20050225
PRAI	EP 2002-19904	A	20020904		
	US 2002-407689P	P	20020904		
	WO 2003-EP9617	W	20030829		

OS MARPAT 140:270839

IT 671821-62-8P 671821-64-0P 671821-66-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phenylbenzonaphthyridine derivs. as PDE3/4 inhibitors)

RN 671821-62-8 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1S)-1-methyl-2-[(4-nitrobenzoyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-64-0 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-N-[(1R)-1-methyl-2-[(4-nitrobenzoyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-66-2 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 671821-47-9P 671821-49-1P 671821-51-5P
671821-53-7P 671821-55-9P 671821-56-0P
671821-58-2P 671821-60-6P 671821-68-4P
671821-70-8P 671821-72-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylbenzonaphthyridine derivs. as PDE3/4 inhibitors)
RN 671821-47-9 CAPLUS
CN Benzeneacetic acid, (2S)-2-[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl](1-methylethyl)amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-49-1 CAPLUS
CN Benzamide, N-[(1S)-2-(benzoyloxy)-1-methylethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-51-5 CAPLUS
CN Benzoic acid, 3,4-dimethoxy-, (2S)-2-[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl](1-methylethyl)amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-53-7 CAPLUS
CN Benzoic acid, 3,5-dimethoxy-, (2S)-2-[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl](1-methylethyl)amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-55-9 CAPLUS
CN Benzamide, N-[(1S)-2-(acetyloxy)-1-methylethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 671821-56-0 CAPLUS
CN Benzamide, N-[3-(benzoyloxy)-1-methylpropyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-58-2 CAPLUS
CN Benzeneacetic acid, 3-[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl](1-methylethyl)amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-60-6 CAPLUS
CN Benzeneacetic acid, 3,4-dimethoxy-, 3-[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl](1-methylethyl)amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671821-68-4 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1R)-2-hydroxy-1-methylethyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 671821-70-8 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-N-(1-methylethyl)benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 671821-66-2
CMF C29 H39 N3 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 671821-72-0 CAPLUS
CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-N-(1-methylethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 671821-66-2
CMF C29 H39 N3 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.42	184.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'REGISTRY' ENTERED AT 12:26:30 ON 19 JAN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2
DICTIONARY FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525566.str

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.